0
Clinical Investigations: PLEURAL DISEASES |

Intrapleural Infusion of Activated Macrophages and γ-Interferon in Malignant Pleural Mesothelioma*: A Phase II Study

Isabelle Monnet, MD; Jean-Luc Breau, MD; Denis Moro, MD; Hervé Lena, MD; Jean-Christophe Eymard, MD; Olivier Ménard, MD; Jean-Philippe Vuillez, MD; Mohamed Chokri, PhD; Jean-Loup Romet-Lemonne, MD; Manuel Lopez, MD, FCCP
Author and Funding Information

*From the Department of Pneumology (Dr. Monnet), Center Hospitalier Intercommunal de Créteil, Créteil; the Department of Oncology (Dr. Breau), Hôpital Avicenne, Bobigny; Department of Pneumology (Dr. Moro), Center Hospitalo-Universitaire, Grenoble; Department of Pneumology (Dr. Lena), Hôpital Pontchaillou, Rennes; Institut Jean Godinot (Dr. Eymard), Reims; Department of Pneumology (Dr. Ménard), Hôpital de Brabois, Vandoeuvre-les-Nancy; Service de Médecine Nucléaire (Dr. Vuillez), Center Hospitalo-Universitaire, Grenoble; Immuno-Designed Molecules (Drs. Chokri and Romet-Lemonne), Paris; and Inserm U76 (Dr. Lopez), Laboratoire de Thérapie Cellulaire, Faculté de Médecine Saint Antoine, Paris, France.

Correspondence to: Manuel Lopez, MD, FCCP, Laboratoire de Thérapie Cellulaire, Faculté de Médecine Saint Antoine, 27 rue de Chaligny, 75012 Paris, France; e-mail: manuel.lopez@chusa.jussieu.fr



Chest. 2002;121(6):1921-1927. doi:10.1378/chest.121.6.1921
Text Size: A A A
Published online

Study objectives: Intrapleural immunotherapy has shown some activity in patients with malignant mesothelioma. We conducted a multicentric pilot phase II study to evaluate the tolerance and the activity of intrapleurally infused autologous human activated macrophages (AMΦ) in patients with stage IA, IB, and IIA malignant pleural mesothelioma (MPM).

Design: AMΦ derived from in vitro monocyte culture were infused into the pleura of patients every week for 8 consecutive weeks. Each infusion was followed 3 days later by an intrapleural injection of 9 millions units of γ-interferon (γ-IFN) in an attempt to prolong the in vivo activation of infused AMΦ. Response was assessed by CT scan and thoracoscopy when possible. If the patient’s disease progressed after AMΦ treatment, an additional treatment was left to the choice of the investigator.

Patients: Nineteen patients with histologically proven stage IA, IB, or IIA MPM were enrolled. Two patients were excluded before any AMΦ infusion because of complications impeding infusion. Seventeen patients were actually treated. After completion of the AMΦ cellular therapy, 10 patients were treated with chemotherapy as their diseases progressed.

Results: The overall response rate of patients actually treated was 14%. When including the two patients enrolled but not treated, the overall response “in intention to treat” was 11%; two patients had a partial response, with a duration of response of 30 months and 3 months, respectively. One patient, who could not be evaluated by thoracoscopy because of pleural symphysis, is still alive without any clinical or radiologic sign of disease 69 months after treatment. No major adverse effects were observed during the infusion of either AMΦ or γ-IFN, and there was no interruption of treatment because of toxicity. However, symphysis was observed in 7 of 14 patients who received the complete treatment. The median survival of patients actually treated, including those who received chemotherapy after AMΦ, was 29.2 months.

Conclusion: Combined infusion of AMΦ and γ-IFN was well tolerated in patients with MPM; however, it had limited antitumor activity.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543